Education
About Us
Working with TipRanks
Follow Us
Lyell Immunopharma (LYEL)
NASDAQ:LYEL
LYEL Stock Chart & Stats
$25.25
-$0.01(-1.66%)
At close: 4:00 PM EST
$25.25
-$0.01(-1.66%)
Day’s Range― - ―
52-Week Range$7.65 - $34.43
Previous CloseN/A
Volume124.06K
Average Volume (3M)28.02K
Market Cap
$708.06M
Enterprise Value$30.12M
Total Cash (Recent Filing)$319.62M
Total Debt (Recent Filing)$44.28M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Mar 04, 2026EPS Estimate
-2.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding21,243,954
10 Day Avg. Volume32,893
30 Day Avg. Volume28,022
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.44
Price to Sales (P/S)2743.40
P/FCF Ratio-1.03
Enterprise Value/Market Cap0.04
Enterprise Value/Revenue734.67
Enterprise Value/Gross Profit734.67
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$20.00Price Target Upside-20.79% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst UpgradeAnalyst upgrades shares of Lyell to Buy from the prior Neutral and raises the price target to $45, reflecting increased conviction following a constructive KOL call on Colorectal Cancer.
Clinical SuccessNew expert feedback confirms that Lyell's existing LYL273 dataset is already clearing the clinical high jump for success in late-line Colorectal Cancer by a wide margin.
Leadership In The FieldThe strategic reset by competitors places Kite behind Lyell, removing a primary near-term threat and affirming Lyell's leadership in the field.
Bears Say
Data LimitationsThe dataset is quite small, and durability remains immature with a limited number of events, making it difficult to support confident projections of long-term durability or commercial viability.
Safety ConcernsThe safety profile remains unproven due to a colitis-related fatality and the subsequent need for protocolized diarrhea prophylaxis.
Uncertain ProjectionsWithout more definitive durability and clearer evidence that toxicity can be reliably managed at scale, there is not yet conviction in the projections.
Lyell Immunopharma News
LYEL FAQ
What was Lyell Immunopharma’s price range in the past 12 months?
Lyell Immunopharma lowest stock price was $7.65 and its highest was $34.43 in the past 12 months.
What is Lyell Immunopharma’s market cap?
Lyell Immunopharma’s market cap is $708.06M.
When is Lyell Immunopharma’s upcoming earnings report date?
Lyell Immunopharma’s upcoming earnings report date is Mar 04, 2026 which is in 70 days.
How were Lyell Immunopharma’s earnings last quarter?
Lyell Immunopharma released its earnings results on Nov 12, 2025. The company reported -$2.13 earnings per share for the quarter, beating the consensus estimate of -$2.468 by $0.338.
Is Lyell Immunopharma overvalued?
According to Wall Street analysts Lyell Immunopharma’s price is currently Overvalued.
Does Lyell Immunopharma pay dividends?
Lyell Immunopharma does not currently pay dividends.
What is Lyell Immunopharma’s EPS estimate?
Lyell Immunopharma’s EPS estimate is -2.37.
How many shares outstanding does Lyell Immunopharma have?
Lyell Immunopharma has 21,243,954 shares outstanding.
What happened to Lyell Immunopharma’s price movement after its last earnings report?
Lyell Immunopharma reported an EPS of -$2.13 in its last earnings report, beating expectations of -$2.468. Following the earnings report the stock price went down -1.248%.
Which hedge fund is a major shareholder of Lyell Immunopharma?
Currently, no hedge funds are holding shares in LYEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lyell Immunopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$20.00 (-20.79% Downside)
$20.00 (-20.79% Downside)
Hedge Fund Trend
Decreased
By 98.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.35%
12-Months-Change
Fundamentals
Return on Equity
-75.75%
Trailing 12-Months
Asset Growth
-34.12%
Trailing 12-Months
Company Description
Lyell Immunopharma
Lyell Immunopharma (LYEL) is a biotechnology company focused on developing innovative cell therapies to treat cancer, particularly solid tumors. The company operates within the biopharmaceutical sector and utilizes its proprietary technology platform to engineer T cells for enhanced anti-tumor activity. Lyell's core products include a pipeline of cell therapy candidates aimed at improving the efficacy and safety of cancer treatments, leveraging advancements in immunotherapy.
LYEL Stock 12 Month Forecast
Average Price Target
$20.00
▼(-20.79% Downside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
Mereo Biopharma Group Plc
―
Replimune Group
―
I-MAB
―
Ownership Overview
30.70% Insiders
7.49% Mutual Funds
36.24% Other Institutional Investors
21.54% Public Companies and
Individual Investors